Technical research and architecture documentation covering blockchain genomics, BioIP protocol, and decentralized biodata infrastructure.
Documents the complete diagnostic investigation of a 1.11 TiB PacBio HiFi plus ONT long-read genome (59 raw objects, 273 total datasets) for an undiagnosed multisystem proband, anchored to the Ehlers-Danlos spectrum. Eleven biofs pipeline verbs were built and executed through a three-node biofs-node orchestration topology with GPU auto-discovery. Cross-platform validation achieved 93.4% SNV concordance, SV F1 = 0.767, and methylome Pearson r = 0.913. A six-tier diagnostic hunt, ACMG/AMP clinical classification, VUS reclassification (8-agent workflow), a phenotype-free whole-genome scan removing all OMIM/panel biases (53 agents, 4.8M tokens), and an assembly-based capstone all converge on the same result: no monogenic cause for the hypermobility core. Two actionable findings returned: compound-heterozygous ALDOB for hereditary fructose intolerance (treatable) and TTN A-band truncation (dominant-DCM secondary finding). All data consent-gated on-chain by BioNFT #5 on Sequentia, with full BioCID provenance trees and proof of compute.
Read Whitepaper →A consent-gated, provenance-verifiable protocol that lets AI agents from different vendors (Claude, Grok, and Gemini) co-interpret one patient genome on a single shared, append-only, hash-chained workspace. Introduces three combined ideas: content-addressed conversation (every agent claim cryptographically bound to the exact immutable data version it was made from), cross-vendor adversarial co-interpretation (models with different failure modes cross-checking each other through a confidence-weighted consensus over structured ACMG classifications), and consent-gated agent cognition (revocable patient consent under GDPR Article 17 governing data access, with the transcript de-identified by design). Per-agent EIP-712 signatures provide non-repudiable authorship, and an independent offline verifier lets any third party re-check the chain and signatures with zero trust.
Read Whitepaper →Proposes a unified architecture for digital and biological evidence authentication using cryptographic hashing, RFC822 email provenance, blockchain anchoring, and BioNFTs, all admissible under Federal Rules of Evidence 902(14). Introduces the LegalEvidenceRegistry smart contract on Sequentias chain (with Avalanche C-Chain redundancy) that anchors SHA-256 hashes of RFC822 emails, biospecimen tokenization records, and clinical-trial documents into a single courtroom-defensible provenance model. Demonstrates that the legal recognition pattern established for digital records over the past decade is now ready to extend to the biological substrate itself, with biobank chain-of-custody admissible under the same FRE 902(14) standard.
Read Whitepaper →Presents AutoDiagnosis, an AI-agentic bioinformatics pipeline that combines multi-sample whole exome sequencing, systematic variant caller false-negative rescue, structural variant analysis, and 21-annotator functional scoring to diagnose previously unresolved rare disease cases. Applied to an undiagnosed adult male with short stature, skeletal dysplasia, and neuromotor involvement, the pipeline processed four independent exome libraries through GPU-accelerated variant calling (NVIDIA Clara Parabricks DeepVariant), identified 279 systematic false-negatives in the CNN-based caller, performed 4-sample Manta structural variant analysis, and assembled an oligogenic diagnostic model implicating seven candidate genes. Demonstrates that AI-orchestrated multi-sample concordance with false-negative rescue resolves cases where single-sample clinical WES fails.
Read Whitepaper →Presents GenoClaw, a system that transforms patient-owned BioWallets into autonomous AI health agents running inside NVIDIA NemoClaw/OpenShell sandboxes with kernel-level isolation. Each agent has access to the patient’s HIPAA-filtered clinical records (via Epic FHIR R4) and genomic variants (via Clara Parabricks DeepVariant), powered by GPT-OSS-120B through Cloudflare Workers AI. Demonstrates end-to-end results: 2.87M variant records processed in 99 seconds on A100 GPU, 1,463 FHIR clinical records imported from UCSF Health, 351 oncology-annotated variants, and real-time AI-powered clinical-genomic correlation. Introduces Metamorphic Consent, BioPIL revocable licensing on Sequentia blockchain, and x402 BioRouter for agent-to-agent micropayment data commerce.
Read Whitepaper →A practical guide to self-directed mRNA cancer immunotherapy for patients who want to take control of their treatment. Step-by-step instructions for retaining your tumor tissue, getting it sequenced, identifying your neoantigens, finding a CDMO to manufacture your personalized vaccine, and navigating regulatory pathways like Right to Try. Includes cost breakdown ($30K-80K) and timeline (8-12 weeks).
Read Guide →This whitepaper presents a patient co-ownership model enabled by Biosample NFT (BioNFT) technology—blockchain-based digital tokens that establish verifiable chain of custody, encode revocable consent, and preserve patient sovereignty from biopsy through vaccine delivery. Demonstrates the technical feasibility and regulatory pathways for enabling individual patients to retain ownership of their neoantigen sequences while accessing GMP-grade mRNA manufacturing through CDMO partnerships. Creates a parallel pathway for patients who choose to exercise sovereignty over their own biology.
Read Whitepaper →A public database and protocol for shared cancer neoantigen sequences derived from common driver mutations (KRAS G12D, BRAF V600E, TP53 hotspots). Unlike private patient-specific neoantigens, shared neoantigens from hotspot mutations are identical across all patients and can be pre-computed, validated, and made freely available. Defines the data architecture, HLA-peptide binding matrices, pre-designed mRNA sequences, and Story Protocol attribution layer enabling a public commons for cancer vaccine development.
Read Whitepaper →A comprehensive proposal for blockchain-based orchestration of GA4GH Passport 2.0 using Cosmos SDK. Maps GA4GH concepts to blockchain primitives: Data Passports → Biosample NFTs (consent tokens with DUO codes), Researcher Passports → Soulbound identity tokens, Data Visas → On-chain ControlledAccessGrants (DAC approvals), and Policy Engine → Smart Contracts (automated DUO code matching). Proposes Broad Institute Consortia Blockchain with validator governance, self-sovereign identity for researchers and patients, immutable audit trails, and backward compatibility with AAI 1.2. Includes detailed Cosmos SDK module design, migration path, and comparison with centralized approaches. Draft for GA4GH DSWS review.
Read Whitepaper →A comprehensive technical specification for BioFS Protocol—a blockchain-based system for federated genomic data discovery using cryptographic fingerprints, dual-chain NFT minting, and automated laboratory onboarding.
Read Whitepaper →A comprehensive whitepaper addressing the clinical trial data loss crisis through patient-owned genomic data vaults secured by blockchain technology. Using HER2-positive breast cancer trials for Enhertu development as a case study, this paper demonstrates how patient-controlled infrastructure enables longitudinal research, cross-institutional collaboration, and ethical data reuse while preserving patient autonomy, attribution, and economic participation. Features the GenoVault architecture combining BioFS Protocol for federated data discovery and x402 BioData Router for cryptographic consent management.
Read Whitepaper →A novel architecture combining Coinbase's x402 HTTP-native payment protocol with Story Protocol's Programmable IP Licensing framework to create a patient-centric, cross-lab genomic analysis network. Demonstrates complete 5-step pipeline from FASTQ to clinical reports with Byzantine-fault-tolerant quality assurance.
Read Whitepaper →A comprehensive technical specification for Sequentia Network (Chain ID: 15132025)—a specialized Layer-1 blockchain designed for genomic data federation, bioinformatics computation, and programmable licensing, featuring BioData Router smart contract, BioFS Protocol, LabNFTs, BioNFTs, Story Protocol integration, and partner chains including OpenCRAVAT, AlphaGenome, SOMOS DAO, AlphaFold, and Claude AI.
Read Whitepaper →